News

In today’s Pharma Pulse, FDA leadership changes with Makary’s resignation, Lilly shares new Zepbound and GLP-1 data, and new study data on prior authorization reform outlook.

US pharma supply chains are shifting amid regulation and geopolitics, with BIOSECURE driving less Asia reliance and more complex, distributed networks.

Will Shrank, MD, explains the main hurdles to specialty therapy access, and what will impact the market over the next few years.

Jessica Lovett explains the importance of being connected to the broader access ecosystem and how leveraging partnerships that can provide global insight and intelligence.

FDA commissioner Marty Makary is planning to resign today, according to sources close to the White House.

Tommy Bramley breaks down the benefits of incorporating real world evidence and data early into a product's lifecycle.

Decision intelligence helps pharma unify small molecule and cell and gene therapy supply chains through AI-driven, automated decision-making.

AI-driven cold chain visibility is only as reliable as the data behind it, exposing gaps between compliance, monitoring, and true product conditions.

Live from Asembia AXS26, Kim Plesnarski shares what a best-in-class reimbursement and support model looks like.

For drugs already on the market, there may be little companies can do to limit business impact; however, for new development drugs, there are some critical considerations.

Bill McElnea and Hinal Sharma discuss how the role of a specialty pharmacy will evolve in the next few years.

Live from Asembia AXS26, Austin Russian examines how specialty therapy launches are evolving.

Angelini Pharma is acquiring Catalyst Pharmaceuticals in a $4.1 billion transaction that expands its presence in the US rare disease market and adds a portfolio of neuromuscular and neurological therapies.

Jennifer Lospinoso shares how cell and gene therapy access models differ from normal specialty medications, and how the market will adapt in the next five years.

Will Shrank, MD, explains how the specialty pharma pipeline could pose access risks in the future.

Miranda Delatore and Megan Wetzel share their outlook on the future of specialty pharmacy.

In this week's Pharma Pulse, Eli Lilly opens its new genetic medicine plant, Bayer acquires Perfuse Therapeutics, and more.

Jessica Lovett discusses specialty pharma commercialization timelines, and how the Canadian market is different from the US.

The facility opening corresponds with a new $4.5 billion capital commitment across two of Lilly's three sites in Lebanon, Indiana.

Tommy Bramley explains how real-world evidence can be leveraged to benefit patient outcomes in specialty pharma.

Live from Asembia AXS26, Austin Russian explains how access to rare disease treatments can be delayed.

Bill McElnea and Hinal Sharma discuss the evolving role of a specialty pharmacy.

Kieran Daly explains how adherence and proof of use strategies improve commercial outcomes and the patient experience in specialty pharma.

As specialty drug costs rise, employers and sponsors must balance alternative funding programs and in-benefit optimization to achieve sustainable savings without disrupting patient care.

Kim Plesnarski explains what the biggest inefficiencies are in specialty pharma partnerships.

Joel Wayment discusses how the cold chain can be more sustainable.

GoodRx now offers oral Ozempic as an alternative to injectable GLP-1 therapies.

Jennifer Lospinoso explains how cell and gene therapies are reshaping specialty pharmacy commercialization.